09 March 2021>: Original Paper
Urinary C-X-C Motif Chemokine 10 Is Related to Acute Graft Lesions Secondary to T Cell- and Antibody-Mediated Damage
Alvaro Arnau 1BEF , Adalberto Benito-Hernández 1ABCDEFG , María Angeles Ramos-Barrón 1BCDF , María Teresa García-Unzueta 2BCDF , José Javier Gómez-Román 3BCDF , José María Gómez-Ortega 3BCDF , Marcos López-Hoyos 4BCDFG , David San Segundo 4BCDF , Juan Carlos Ruiz 1BCDFG , Emilio Rodrigo 1ABCDEFG*DOI: 10.12659/AOT.929491
Ann Transplant 2021; 26:e929491
Table 4 Variables related to subclinical antibody-mediated rejection (AbMR) and T cell-mediated rejection (TCMR).
No AbMR (n=69) | AbMR (n=23) | p | No TCMR (n=77) | TCMR (n=15) | p | |
---|---|---|---|---|---|---|
Recipient age (years) | 52.1±11.9 | 49.8±11.7 | 0.429 | 51.3±12.1 | 52.6±10.7 | 0.694 |
Recipient gender (Male) | 63.8% | 52.2% | 0.342 | 63.6% | 46.7% | 0.218 |
Donor age (years) | 49.7±12.9 | 55.2±11.9 | 0.073 | 50.8±12.9 | 52.6±12.6 | 0.625 |
Life donor | 7.2% | 21.7% | 0.053 | 9.1% | 20.0% | 0.214 |
ECD | 26.1% | 47.8% | 0.052 | 29.9% | 40.0% | 0.440 |
DCD | 27.5% | 21.7% | 0.583 | 27.3% | 20.0% | 0.557 |
Mismatches | 4.0±1.3 | 4.1±1.4 | 0.784 | 4.0±1.3 | 4.1±1.3 | 0.885 |
CIT (hours) | 14.3±7.4 | 15.0±9.5 | 0.740 | 14.8±7.9 | 12.9±7.9 | 0.397 |
SPK | 15.9% | 8.7% | 0.388 | 13.0% | 20.0% | 0.476 |
Pretransplant DSA | 0.0% | 26.1% | 6.5% | 6.7% | 0.980 | |
Current PRA (%) | 0.4±3.3 | 5.4±20.6 | 0.258 | 1.9±11.7 | 0.0±0.0 | 0.520 |
Peak PRA >25% | 10.1% | 26.1% | 0.057 | 15.6% | 6.7% | 0.364 |
DSA at biopsy | 5.8% | 60.9% | 15.6% | 40.0% | 0.029 | |
Retransplant | 20.3% | 52.2% | 0.003 | 28.6% | 26.7% | 0.881 |
Prednisone dose (mg) | 3.9±2.4 | 4.8±1.7 | 0.049 | 4.2±2.3 | 3.8±1.9 | 0.613 |
Tacrolimus blood level at biopsy (ng/ml) | 7.9±2.3 | 7.7±2.3 | 0.811 | 7.8±2.3 | 7.6±2.6 | 0.613 |
Basiliximab induction | 18.8% | 17.4% | 0.877 | 18.2% | 20.0% | 0.868 |
Thymoglobulin induction | 47.8% | 65.2% | 0.148 | 54.5% | 40.0% | 0.302 |
DGF | 15.9% | 34.8% | 0.053 | 22.1% | 13.3% | 0.444 |
Creatinine at biopsy (mg/dl) | 1.24±0.43 | 1.65±0.57 | 0.004 | 1.29±0.45 | 1.59±0.66 | 0.036 |
eGFR at biopsy (ml/min/1.73 m) | 66.3±21.1 | 47.4±20.1 | 64±22 | 49±19.2 | 0.015 | |
Proteinuria at biopsy (mg/day) | 579±1167 | 510±451 | 0.785 | 462±743 | 1071±1901 | 0.241 |
CXCL10/Cr at biopsy (ng/mmol) | 11.92±16.08 | 18.26±9.05 | 0.076 | 12.4±15.5 | 19.1±9.6 | 0.111 |
Logarithm of CXCL10/Cr at biopsy | 0.93±0.30 | 1.21±0.22 | 0.95±0.30 | 1.22±0.25 | 0.002 | |
CXCL10/Cr 3 tertile | 15.9% | 52.2% | 0.001 | 19.5% | 53.3% | 0.006 |
ECD – expanded criteria donor; DCD – donation after cardiac death; CIT – cold ischemia time; SPK – simultaneous pancreas and kidney transplant; DSA – donor-specific antibodies; PRA – panel-reactive antibodies; DGF – delayed graft function; eGFR – estimated glomerular filtration rate. |